New data presented at ATS 2024 show the potential of TEZSPIR

WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2024--

Related Keywords

Japan , Cambridge , Cambridgeshire , United Kingdom , Manchester , United States , American , America , Lymphopoietin Isoforms , Dave Singh , Brendan Mcevoy , Jillian Gonzales , Sharon Barr , Global Initiative On Obstructive Lung Disease , Centers For Disease , International Conference , American Thoracic Society , National Heart , Amgen , Astrazeneca , American Lung Association , University Of Manchester , Blood Institute , Global Initiative For Chronic Obstructive Lung Disease , Confidence Interval , Respiratory Pharmacology , Executive Vice President , Respiratory Questionnaire , Asthma Symptoms , Prescribing Information , Patient Informationandinstructions , Obstructive Pulmonary Disease , North America , Rare Diseases , Thoracic Society , Blood Eosinophil Count , Global Initiative , Chronic Obstructive Lung Disease , Disease Control , Leading Causes , Learn More Breathe Better , Ultimate Relationship , One Year Mortality , Their Predictors , Patients Hospitalized , Nationwide Population Based , First Year After Hospitalization , Chronic Obstructive Pulmonary , Obstructive Lung Disease , Atherosclerosis Risk , Stromal Lymphopoietin Isoforms , Inflammatory Disorders , Business Wire ,